Item request has been placed!
×
Item request cannot be made.
×
Processing Request
TRIM14 suppressed the progression of NSCLC via hexosamine biosynthesis pathway.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Wei, Sisi1 (AUTHOR); Ai, Meiling2,3 (AUTHOR); Zhan, Yuan4 (AUTHOR); Yu, Jieqing5 (AUTHOR); Xie, Tao2 (AUTHOR); Hu, Qinghua2 (AUTHOR); Fang, Yang2 (AUTHOR); Huang, Xuan2 (AUTHOR) ; Li, Yong1 (AUTHOR)
- Source:
Carcinogenesis. May2024, Vol. 45 Issue 5, p324-336. 13p.
- Subject Terms:
- Additional Information
- Abstract:
Tripartite Motif 14 (TRIM14) is an oncoprotein that belongs to the E3 ligase TRIM family, which is involved in the progression of various tumors except for non-small cell lung carcinoma (NSCLC). However, little is currently known regarding the function and related mechanisms of TRIM14 in NSCLC. Here, we found that the TRIM14 protein was downregulated in lung adenocarcinoma tissues compared with the adjacent tissues, which can suppress tumor cell proliferation and migration both in vitro and in vivo. Moreover, TRIM14 can directly bind to glutamine fructose-6-phosphate amidotransferase 1 (GFAT1), which in turn results in the degradation of GFAT1 and reduced O -glycosylation levels. GFAT1 is a key enzyme in the rate-limiting step of the hexosamine biosynthetic pathway (HBP). Replenishment of N -acetyl- d -glucosamine can successfully reverse the inhibitory effect of TRIM14 on the NSCLC cell growth and migration as expected. Collectively, our data revealed that TRIM14 suppressed NSCLC cell proliferation and migration through ubiquitination and degradation of GFAT1, providing a new regulatory role for TRIM14 on HBP. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Carcinogenesis is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.